Posted by Michael Wonder on 10 Nov 2017
Institute for Clinical and Economic Review to assess erenumab for migraine prevention; guselkumab and tildrakizumab for plaque psoriasis
9 November 2017 - Open Input now being accepted on both topics; both reviews to be subject to public deliberation at upcoming CTAF meeting.
The ICER will assess the comparative clinical effectiveness and value of erenumab (Amgen/Novartis) for prevention of migraine headaches. The FDA's decision on whether to approve erenumab is expected in May of 2018.
In addition, ICER will conduct an update to its 2016 report on therapies for plaque psoriasis. ICER plans to review new evidence that has emerged on the previously reviewed therapies, as well as evidence on recently-approved guselkumab (Tremfya, Janssen/Johnson & Johnson) and on tildrakizumab (Sun Pharma), which is currently under review by the FDA with an expected decision in March of 2018.
